SG11202108405VA - Methods and systems for determining a pregnancy-related state of a subject - Google Patents

Methods and systems for determining a pregnancy-related state of a subject

Info

Publication number
SG11202108405VA
SG11202108405VA SG11202108405VA SG11202108405VA SG11202108405VA SG 11202108405V A SG11202108405V A SG 11202108405VA SG 11202108405V A SG11202108405V A SG 11202108405VA SG 11202108405V A SG11202108405V A SG 11202108405VA SG 11202108405V A SG11202108405V A SG 11202108405VA
Authority
SG
Singapore
Prior art keywords
pregnancy
subject
systems
determining
methods
Prior art date
Application number
SG11202108405VA
Other languages
English (en)
Inventor
Maneesh Jain
Eugeni Namsaraev
Morten Rasmussen
Joan Camunas Soler
Farooq Siddiqui
Mitsu Reddy
Original Assignee
Mirvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirvie Inc filed Critical Mirvie Inc
Publication of SG11202108405VA publication Critical patent/SG11202108405VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Primary Health Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Bioethics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Physiology (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
SG11202108405VA 2019-02-14 2020-02-13 Methods and systems for determining a pregnancy-related state of a subject SG11202108405VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962805515P 2019-02-14 2019-02-14
US201962890248P 2019-08-22 2019-08-22
US201962926786P 2019-10-28 2019-10-28
PCT/US2020/018172 WO2020168118A1 (fr) 2019-02-14 2020-02-13 Procédé et systèmes de détermination d'un état associé à la grossesse chez un sujet

Publications (1)

Publication Number Publication Date
SG11202108405VA true SG11202108405VA (en) 2021-08-30

Family

ID=72044275

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108405VA SG11202108405VA (en) 2019-02-14 2020-02-13 Methods and systems for determining a pregnancy-related state of a subject

Country Status (10)

Country Link
US (6) US11208693B2 (fr)
EP (1) EP3924972A4 (fr)
JP (1) JP2022519897A (fr)
CN (1) CN113692624A (fr)
AU (1) AU2020221278A1 (fr)
CA (1) CA3126990A1 (fr)
GB (3) GB2612911B (fr)
MX (1) MX2021009726A (fr)
SG (1) SG11202108405VA (fr)
WO (1) WO2020168118A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126990A1 (fr) 2019-02-14 2020-08-20 Maneesh Jain Procede et systemes de determination d'un etat associe a la grossesse chez un sujet
US20210366569A1 (en) * 2019-06-03 2021-11-25 Illumina, Inc. Limit of detection based quality control metric
AU2021213150A1 (en) 2020-01-30 2022-08-04 Prognomiq Inc Lung biomarkers and methods of use thereof
WO2022155469A1 (fr) * 2021-01-15 2022-07-21 The Trustees Of Columbia University In The City Of New York Utilisation du métabolome vaginal pour la prédiction précoce d'une naissance prématurée spontanée
CN112662754B (zh) * 2021-01-27 2024-05-14 北京航空航天大学 用于预测小耳畸形发生概率的组合物的应用方法
WO2022173786A1 (fr) * 2021-02-10 2022-08-18 Mirvie, Inc. Procédés et systèmes pour effectuer des essais cliniques liés à la grossesse
US20220328129A1 (en) * 2021-03-31 2022-10-13 PrognomIQ, Inc. Multi-omic assessment
EP4341438A2 (fr) * 2021-05-18 2024-03-27 Mirvie, Inc. Procédés et systèmes de profilage de méthylation d'états liés à la grossesse
EP4099335A1 (fr) * 2021-06-03 2022-12-07 Tata Consultancy Services Limited Système et procédé d'estimation de la date d'accouchement d'une femme enceinte à l'aide de données sur le microbiome
WO2022256850A1 (fr) * 2021-06-04 2022-12-08 The Board Of Trustees Of The Leland Stanford Junior University Systèmes et méthodes pour évaluer le risque pour la santé des nouveaux-nés et leurs utilisations
US11664100B2 (en) * 2021-08-17 2023-05-30 Birth Model, Inc. Predicting time to vaginal delivery
CN118215845A (zh) 2021-09-13 2024-06-18 普罗科技有限公司 增强的对生物分子的检测和定量
WO2023081768A1 (fr) * 2021-11-04 2023-05-11 Mirvie, Inc. Procédés et systèmes pour déterminer un état associé à la grossesse d'un sujet
WO2023102786A1 (fr) * 2021-12-08 2023-06-15 深圳华大基因股份有限公司 Application d'un marqueur génétique dans la prévention du risque de naissance prématurée chez la femme enceinte
WO2023150726A2 (fr) * 2022-02-03 2023-08-10 Nx Prenatal Inc. Stratification du risque à trois niveaux pour naissance prématurée spontanée
CN114636826B (zh) * 2022-03-02 2022-11-22 广州市妇女儿童医疗中心 Cd177+中性粒细胞在制备新生儿坏死性小肠结肠炎检测产品中的应用
CN114822841A (zh) * 2022-03-24 2022-07-29 川北医学院附属医院 基层适用的严重产后出血风险预测模型及其构建方法
KR20230145829A (ko) * 2022-04-11 2023-10-18 의료법인 성광의료재단 기계학습을 이용한 고위험 임신 질환 예측을 위한 질량 스펙트럼 분석 방법
CN114592074A (zh) * 2022-04-12 2022-06-07 苏州市立医院 一种与胎龄相关的靶标基因组合及其应用
CN116705215B (zh) * 2023-08-04 2023-09-29 南京诺源医疗器械有限公司 一种用于脑室检测的荧光标记系统
CN116904587B (zh) * 2023-09-13 2023-12-05 天津云检医学检验所有限公司 一种用于预测早产的生物标志物组、预测模型及试剂盒
CN117079823B (zh) * 2023-10-17 2024-01-02 北京大学第三医院（北京大学第三临床医学院） 早期预测选择性胎儿生长受限发病风险筛查的系统和方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629147A (en) 1992-07-17 1997-05-13 Aprogenex, Inc. Enriching and identifying fetal cells in maternal blood for in situ hybridization
US5432054A (en) 1994-01-31 1995-07-11 Applied Imaging Method for separating rare cells from a population of cells
CA2702148C (fr) 1999-01-06 2014-03-04 Genenews Inc. Methode de profilage de l'expression genique d'un sujet humain atteint d'une maladie infectieuse
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US6664056B2 (en) 2000-10-17 2003-12-16 The Chinese University Of Hong Kong Non-invasive prenatal monitoring
WO2003095624A2 (fr) 2002-05-10 2003-11-20 Phase-1 Molecular Toxicology, Inc. Genes predictifs d'une inflammation du foie
US20040180048A1 (en) 2002-07-12 2004-09-16 The Johns Hopkins University Neuronal and retinal gene expression patterns
WO2004007673A2 (fr) 2002-07-12 2004-01-22 The Johns Hopkins University Modele d'expression genique neuronale
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
CN100379882C (zh) 2003-01-17 2008-04-09 香港中文大学 作为妊娠相关病症的诊断标志物的循环mRNA
US20060003342A1 (en) 2004-01-15 2006-01-05 Bianchi Diana W Fetal RNA in amniotic fluid to determine gene expression in the developing fetus
CN101389767A (zh) 2004-07-21 2009-03-18 加利福尼亚大学董事会 唾液转录组诊断
US7713693B1 (en) 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
US20060166242A1 (en) 2005-01-06 2006-07-27 Mount Sinai Hospital Markers of pre-term labor
JP5629051B2 (ja) 2005-03-18 2014-11-19 ザ チャイニーズ ユニバーシティー オブ ホンコンＴｈｅ Ｃｈｉｎｅｓｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈｏｎｇｋｏｎｇ 出生前診断およびモニタリングのためのマーカー
EP2030025A2 (fr) 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Marqueurs associés à des événements artério-vasculaires et procédés d'utilisation de ces marqueurs
US20100145131A1 (en) 2007-05-01 2010-06-10 Helena Grinberg-Rashi Methods and kits for predicting cancer metastasis
WO2009009457A1 (fr) 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Microréseau de micro-arn spécifique de la maladie d'alzheimer et procédés apparentés
ES2415245T5 (es) 2007-08-22 2016-12-23 Trovagene, Inc. Métodos de uso de miARN para la detección de muerte celular in vivo
WO2009073629A2 (fr) 2007-11-29 2009-06-11 Complete Genomics, Inc. Procédés de séquençage aléatoire efficace
JP2011510623A (ja) 2008-01-27 2011-04-07 ロゼッタ ゲノミックス エルティーディー． 妊娠の合併症を診断するための方法及び組成物
WO2009134452A2 (fr) 2008-05-01 2009-11-05 Swedish Health Services Analyse de diagnostic d'accouchement prématuré
WO2009143576A1 (fr) 2008-05-27 2009-12-03 Adelaide Research & Innovation Pty Ltd Polymorphismes associés à des complications pendant la grossesse
US20110150775A1 (en) 2008-06-01 2011-06-23 Tufts Medical Center, Inc. Genomic approaches to fetal treatment and diagnosis
US7888030B2 (en) 2008-08-21 2011-02-15 King's College London Biomarkers
US20110263441A1 (en) 2008-10-15 2011-10-27 Golub Todd R Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
AU2010294193B2 (en) 2009-09-11 2014-09-25 The Chinese University Of Hong Kong Methods for assessing liver pathologies
EP2510356B1 (fr) 2009-12-08 2018-10-31 Cedars-Sinai Medical Center Procédé de diagnostic pour identifier des femmes qui présentent un risque d'accouchement avant terme
EP2854057B1 (fr) 2010-05-18 2018-03-07 Natera, Inc. Procédés pour une classification de ploïdie prénatale non invasive
WO2011156734A2 (fr) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Procédé de caractérisation de maladies vasculaires
EP2591366A2 (fr) 2010-07-08 2013-05-15 Pronota NV QUIESCINE Q6 UTILISÉE EN TANT QUE BIOMARQUEUR DE TROUBLES HYPERTENSIFS DE LA GROSSESSE& xA;
CA2806291C (fr) 2010-07-23 2023-08-29 President And Fellows Of Harvard College Procedes de detection de signatures de maladies ou pathologies dans des liquides biologiques
CA2822439A1 (fr) * 2010-12-23 2012-06-28 Sequenom, Inc. Detection de variations genetiques fƒtales
WO2013007708A1 (fr) 2011-07-08 2013-01-17 Helmholtz-Zentrum für Infektionsforschung GmbH Médicament pour le traitement du cancer du foie
US20130040303A1 (en) 2011-08-08 2013-02-14 Eugenia Wang Biomarker for Alzheimer's Disease and/or Mild Cognitive Impairment, and Use Thereof
MX2014003153A (es) 2011-09-30 2014-04-30 Somalogic Inc Prediccion de riesgo de evento cardiovascular y usos del mismo.
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
SG11201505515XA (en) 2012-01-27 2015-09-29 Univ Leland Stanford Junior Methods for profiling and quantitating cell-free rna
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
EP2825665B1 (fr) 2012-03-14 2017-09-06 Ruprecht-Karls-Universität Heidelberg Signatures épigénétiques utilisées comme marqueurs de cardiomyopathies et d'insuffisances du myocarde
WO2014142752A1 (fr) 2013-03-12 2014-09-18 Agency For Science, Technology And Research Biomarqueurs de pré-éclampsie
CN105143887B (zh) 2013-03-15 2018-08-28 私募蛋白质体公司 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
WO2014193999A2 (fr) * 2013-05-28 2014-12-04 Caris Science, Inc. Méthodes et compositions d'identification de biomarqueurs
CN104673925A (zh) 2015-03-19 2015-06-03 绍兴锐创生物科技有限公司 能检测多种新生儿遗传病的rna探针及基因筛查试剂盒
US20180155787A1 (en) 2015-06-05 2018-06-07 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
EP3502705B1 (fr) * 2015-09-11 2020-09-09 Universidad de los Andes Procédé in vitro pour identifier une maladie associée à la grossesse
CN108138232B (zh) 2015-09-14 2023-07-18 基恩菲特公司 用于诊断和评估非酒精性脂肪性肝炎的方法
WO2017141169A1 (fr) * 2016-02-16 2017-08-24 Tata Consultancy Services Limited Procédé et système d'évaluation précoce du risque d'issue d'accouchement prématuré
CN109790643A (zh) 2016-03-09 2019-05-21 分子听诊器公司 用于检测组织状况的方法和系统
CA3126990A1 (fr) 2019-02-14 2020-08-20 Maneesh Jain Procede et systemes de determination d'un etat associe a la grossesse chez un sujet

Also Published As

Publication number Publication date
US20210017598A1 (en) 2021-01-21
US20230250477A1 (en) 2023-08-10
EP3924972A1 (fr) 2021-12-22
US20220073982A1 (en) 2022-03-10
EP3924972A4 (fr) 2023-03-29
US11851706B2 (en) 2023-12-26
US20240117429A1 (en) 2024-04-11
GB2615975A (en) 2023-08-23
WO2020168118A1 (fr) 2020-08-20
US20220380847A1 (en) 2022-12-01
GB2612911B (en) 2023-11-22
US11441183B2 (en) 2022-09-13
CN113692624A (zh) 2021-11-23
GB2597379A (en) 2022-01-26
MX2021009726A (es) 2021-09-14
GB202111725D0 (en) 2021-09-29
GB202308486D0 (en) 2023-07-19
CA3126990A1 (fr) 2020-08-20
JP2022519897A (ja) 2022-03-25
GB2615975B (en) 2023-11-29
GB202216607D0 (en) 2022-12-21
GB2612911A (en) 2023-05-17
GB2597379B (en) 2022-12-28
AU2020221278A1 (en) 2021-08-05
US11845988B2 (en) 2023-12-19
US11208693B2 (en) 2021-12-28
US20220380846A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
GB2597379B (en) Methods and systems for determining a pregnancy-related state of a subject
EP3658941A4 (fr) Systèmes et procédés de détermination d'un temps de réserve d'un monobloc
PL3669942T3 (pl) Systemy oraz sposoby określania obszaru będącego przedmiotem zainteresowania w badanym obiekcie
EP3455840A4 (fr) Systèmes et procédés de détermination d'heure d'arrivée estimée
GB202303135D0 (en) Methods and systems for determining a pregnancy-related state of a subject
HUE051292T2 (hu) Rendszerek és eljárások becsült érkezésû idõ meghatározására
GB2594180B (en) Methods and systems for speech detection
IL290612A (en) Systems and methods for protein prediction
IL267885B (en) Methods and systems for calculating the presence of items
EP3635706A4 (fr) Procédés et systèmes d'estimation de l'heure d'arrivée
IL291284A (en) Systems and methods for expression of proteins
EP3976825A4 (fr) Systèmes et procédés pour déterminer une séquence
EP3652761A4 (fr) Système et procédé de détermination de l'âge d'un transformateur
GB2586659B (en) Inspection related systems and methods
EP3985207C0 (fr) Systèmes de coffrage et procédés associés
EP3874773A4 (fr) Systèmes et procédés de détermination de l'emplacement et de la distance d'un terminal
IL286081A (en) Method and system for determining the position of forms
EP3613975C0 (fr) Procédé et système pour déterminer une cause d'une surconsommation de carburant
EP4025875C0 (fr) Méthode et système pour déterminer déplacements de position
EP4051127A4 (fr) Procédés et systèmes d'analyse de menstrualome
PL3537654T3 (pl) Sposób i układ do określania konfiguracji interfejsu
EP3908919A4 (fr) Systèmes et procédés de définition de fenêtres de calcul
GB2585791B (en) Systems and methods for measuring bending of a tool
GB2585826B (en) Systems and methods for activating functionality
GB2567889B (en) Method and system for determining a direction of movement of an object